138 related articles for article (PubMed ID: 36870603)
1. Minimal/Measurable Residual Disease Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor.
Tung JK; Jangam D; Ho CC; Fung E; Khodadoust MS; Kim YH; Zehnder JL; Stehr H; Zhang BM
J Mol Diagn; 2023 Jun; 25(6):331-341. PubMed ID: 36870603
[TBL] [Abstract][Full Text] [Related]
2. How I investigate minimal residual disease in acute lymphoblastic leukemia.
Correia RP; Bento LC; de Sousa FA; Barroso RS; Campregher PV; Bacal NS
Int J Lab Hematol; 2021 Jun; 43(3):354-363. PubMed ID: 33423385
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies.
Hussaini MO; Srivastava J; Lee LW; Nishihori T; Shah BD; Alsina M; Pinilla-Ibarz J; Shain KH
Arch Pathol Lab Med; 2022 Apr; 146(4):485-493. PubMed ID: 34343238
[TBL] [Abstract][Full Text] [Related]
4. High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.
Salson M; Giraud M; Caillault A; Grardel N; Duployez N; Ferret Y; Duez M; Herbert R; Rocher T; Sebda S; Quief S; Villenet C; Figeac M; Preudhomme C
Leuk Res; 2017 Feb; 53():1-7. PubMed ID: 27930944
[TBL] [Abstract][Full Text] [Related]
5. Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.
Reyes-Barron C; Burack WR; Rothberg PG; Ding Y
Crit Rev Oncog; 2017; 22(5-6):559-567. PubMed ID: 29604931
[TBL] [Abstract][Full Text] [Related]
6. High-throughput sequencing of peripheral blood for minimal residual disease monitoring in childhood precursor B-cell acute lymphoblastic leukemia: A prospective feasibility study.
Bartram J; Wright G; Adams S; Archer P; Brooks T; Edwards D; Hancock J; Knecht H; Inglott S; Mountjoy E; Roynane M; Wakeman S; Moppett J; Hubank M; Goulden N
Pediatr Blood Cancer; 2022 Mar; 69(3):e29513. PubMed ID: 34971078
[TBL] [Abstract][Full Text] [Related]
7. One-Step Next-Generation Sequencing of Immunoglobulin and T-Cell Receptor Gene Recombinations for MRD Marker Identification in Acute Lymphoblastic Leukemia.
Villarese P; Abdo C; Bertrand M; Thonier F; Giraud M; Salson M; Macintyre E
Methods Mol Biol; 2022; 2453():43-59. PubMed ID: 35622319
[TBL] [Abstract][Full Text] [Related]
8. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
Brüggemann M; Kotrová M; Knecht H; Bartram J; Boudjogrha M; Bystry V; Fazio G; Froňková E; Giraud M; Grioni A; Hancock J; Herrmann D; Jiménez C; Krejci A; Moppett J; Reigl T; Salson M; Scheijen B; Schwarz M; Songia S; Svaton M; van Dongen JJM; Villarese P; Wakeman S; Wright G; Cazzaniga G; Davi F; García-Sanz R; Gonzalez D; Groenen PJTA; Hummel M; Macintyre EA; Stamatopoulos K; Pott C; Trka J; Darzentas N; Langerak AW;
Leukemia; 2019 Sep; 33(9):2241-2253. PubMed ID: 31243313
[TBL] [Abstract][Full Text] [Related]
9. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
10. High-throughput sequencing of immunoglobulin heavy chain for minimal residual disease detection in B-lymphoblastic leukemia.
Correia RP; Puga RD; Muto NH; Lee MLM; Torres DC; Hassan R; Bacal NS; Hamerschlak N; Campregher PV
Int J Lab Hematol; 2021 Aug; 43(4):724-731. PubMed ID: 33393719
[TBL] [Abstract][Full Text] [Related]
11. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
13. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
Kotrova M; Trka J; Kneba M; Brüggemann M
Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
[TBL] [Abstract][Full Text] [Related]
14. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
Chan DW; Liang R; Kwong YL; Chan V
Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
[TBL] [Abstract][Full Text] [Related]
15. Multi-loci diagnosis of acute lymphoblastic leukaemia with high-throughput sequencing and bioinformatics analysis.
Ferret Y; Caillault A; Sebda S; Duez M; Grardel N; Duployez N; Villenet C; Figeac M; Preudhomme C; Salson M; Giraud M
Br J Haematol; 2016 May; 173(3):413-20. PubMed ID: 26898266
[TBL] [Abstract][Full Text] [Related]
16. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia.
Wu D; Sherwood A; Fromm JR; Winter SS; Dunsmore KP; Loh ML; Greisman HA; Sabath DE; Wood BL; Robins H
Sci Transl Med; 2012 May; 4(134):134ra63. PubMed ID: 22593176
[TBL] [Abstract][Full Text] [Related]
17. Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.
Della Starza I; De Novi LA; Santoro A; Salemi D; Tam W; Cavalli M; Menale L; Soscia R; Apicella V; Ilari C; Vitale A; Testi AM; Inghirami G; Chiaretti S; Foà R; Guarini A
Leuk Lymphoma; 2019 Nov; 60(11):2838-2840. PubMed ID: 31050551
[No Abstract] [Full Text] [Related]
18. Developing an Unbiased Multiplex PCR System to Enrich the
Wu J; Wang X; Lin L; Li X; Liu S; Zhang W; Luo L; Wan Z; Fang M; Zhao Y; Wang X; Mai H; Yuan X; Wen F; Li C; Liu X
Front Immunol; 2020; 11():1631. PubMed ID: 32849555
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefit of a high-throughput sequencing approach for minimal residual disease in acute lymphoblastic leukemia.
Wright G; Watt E; Inglott S; Brooks T; Bartram J; Adams SP
Pediatr Blood Cancer; 2019 Aug; 66(8):e27787. PubMed ID: 31034760
[TBL] [Abstract][Full Text] [Related]
20. Using synthetic templates to design an unbiased multiplex PCR assay.
Carlson CS; Emerson RO; Sherwood AM; Desmarais C; Chung MW; Parsons JM; Steen MS; LaMadrid-Herrmannsfeldt MA; Williamson DW; Livingston RJ; Wu D; Wood BL; Rieder MJ; Robins H
Nat Commun; 2013; 4():2680. PubMed ID: 24157944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]